North American gets FDA approval for breast cancer treatment
16th Nov 2006, 08:21 GMT
North American Scientific got approval from the FDA to market a high-dose radiation design of its breast cancer treatment or internal radiation, product ClearPath and its design.
North American gets FDA approval for breast cancer treatment related news:
- North American gets FDA approval for breast cancer treatment — Latest news from Los Angeles Business from bizjournals
- North American Gets Cancer Treatment OK — FDA News News from StratCenter.com
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System — FDA News News from StratCenter.com
- Cancer treatment of black women delayed — United Press International - Consumer Health
- Shorter-course Radiation Treatment Safe For Breast Cancer — Health News from Medical News Today
- Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer — News-Medical News Feed
- Research Finds Shorter-course Radiation Treatment Safe For Breast Cancer — ScienceDaily Headlines
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer — Medscape Pathology Headlines
- Surgical Biopsy May Reveal Cancer In Women With Rare But Benign Breast Condition — ScienceDaily Headlines
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting